

Review of: "[Case Report] Profound Symptom Alleviation in Long-Covid Patients After PAMP-Immunotherapy: Three Case Reports"

Alan Cash

Potential competing interests: I am an executive in a company that is testing Long COVID medications in clinical trials.

Being able to treat Long COVID is of crucial importance. A low-cost, low-risk treatment option is of critical importance for the many countries, and this work is vital.

The results of Case study 1 are certainly impressive. Case studies 2 and 3 contain support, but lack rigorous descriptions.

The authors should consider providing the drugs used in the treatment, the method of treatment, and the dosage. This would be a minimum for publication, I would think.